France Medical Devices Market Report 2026: LPP Listing, ANSM Regulation, and Hospital Procurement Intelligence

The French medical devices market is estimated at EUR 14–16 billion in 2026, making it the third-largest medical device market in the EU after Germany and the UK. France has approximately 3,000 hospitals and clinics, 74,000 pharmacies, and a strong tradition of medical device innovation through companies including Laboratoires Urgo, Vygon, and Coloplast France. The market is segmented between hospital procurement (approximately 60%) and outpatient/community care (40%). Private clinic groups (Elsan, Ramsay Santé, Almaviva Santé) represent a growing procurement channel alongside the public AP-HP (Assistance Publique-Hôpitaux de Paris) and regional CHU (Centre Hospitalier Universitaire) networks.

ANSM (Agence nationale de sécurité du médicament et des produits de santé) is France's national competent authority for medical devices under EU MDR 2017/745 and IVDR 2017/746. CE marking via an EU Notified Body is required for Class IIa, IIb, and III devices. ANSM conducts post-market surveillance, manages the French vigilance system (signalement incidents), and contributes to EMA Notified Body oversight. ANSM operates a dedicated medical device registration system (DMDIV for IVDs) and runs ANSM medical device warning communications. For clinical investigations, French ethics committees (CPP, Comités de Protection des Personnes) are required alongside ANSM authorisation.

Medical devices eligible for Assurance Maladie reimbursement must be listed on the LPP (Liste des Produits et Prestations). The LPP is maintained by the CNAM and managed through HAS assessment. HAS CNEDIMTS (Commission nationale d'évaluation des dispositifs médicaux et des technologies de santé) evaluates the ASA (added value in medical service rendered) of new devices seeking LPP listing. The ASA level determines the reimbursement tariff. Hospital devices used within DRG-funded procedures are typically financed within the GHS (Groupement Homogène de Séjours) tariff, though the LPPR/LPP lists hospital-specific high-cost implants that receive separate add-on payment.

Forfait Innovation (FI) is France's early access pathway for genuinely innovative medical devices that cannot be adequately reimbursed within existing DRG or LPP frameworks. Under FI, innovative devices can receive temporary conditional reimbursement while real-world evidence is collected in French hospitals. The program requires HAS designation as "innovative" and evidence generation commitments from the manufacturer. Forfait Innovation has covered advanced surgical robotics, novel cardiac devices, and precision diagnostics. It is the key market access pathway for novel medtech seeking rapid French hospital access before full LPP listing.

GHT (Groupements Hospitaliers de Territoire) are territorial hospital groups introduced by the Loi de Modernisation du Système de Santé (2016), pooling procurement, clinical protocols, and administrative functions across public hospitals in a defined territory. France has approximately 135 GHTs, each coordinating device procurement for their member hospitals. GHT lead purchasing hospitals negotiate framework contracts on behalf of their entire group. This consolidation means that securing a GHT contract provides access to multiple hospital sites simultaneously — making GHT lead hospital tender decisions critical commercial milestones for device manufacturers.

BioNixus supports French and European medical device manufacturers in entering GCC and MENA markets. Our services include SFDA (Saudi Arabia), MOHAP/DHA/DOH (UAE), HMC (Qatar), and GCC-wide regulatory pathway mapping; hospital procurement intelligence at key GCC accounts; distributor network evaluation; primary research with biomedical engineers and clinical procurement specialists; and comparative France vs. GCC commercial strategy. BioNixus operates from London with in-country field teams across Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, and Egypt.